The recognition that increased serum FGF21 expression in patients with obesity/type 2 diabetes (T2D) compensates for pathologic metabolic changes [30, 31] led us to further dissect the role of FGF21 in the ischemic cascade after stroke. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.